Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 6/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GSR | P00390 | 2/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981829 | 0.89 | CFTR (0.66) | CFTRKDM4EALDH1A1GAAHPGD | |
| SCHEMBL981372 | 0.88 | CFTR (0.58) | CFTRKDM4EALDH1A1GAAHPGD | |
| SCHEMBL981611 | 0.87 | CFTR (0.60) | CFTRALDH1A1ADORA2A | |
| SCHEMBL29847411 | 0.87 | CFTR (0.78) | CFTRKDM4EALDH1A1GAAHPGD | |
| SCHEMBL981277 | 0.87 | CFTR (0.78) | CFTRKDM4EALDH1A1GAAHPGD | |
| SCHEMBL16063405 | 0.86 | CFTR (0.59) | CFTRKDM4EALDH1A1GAAHPGD | |
| SCHEMBL19032847 | 0.85 | CFTR (1.00) | CFTRALDH1A1 | |
| SCHEMBL3441312 | 0.83 | CFTR (0.71) | CFTRKDM4EALDH1A1GAAHPGD | |
| SCHEMBL3441266 | 0.79 | CFTR (0.66) | CFTRKDM4EALDH1A1GAAHPGD | |
| SCHEMBL28515712 | 0.79 | KDM4E (0.69) | CFTRKDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247580-B1 | QUINOXALINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2015-07-08 | — | — | EP | claimed |
| US-8835634-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-09-16 | — | — | US | claimed |
| US-20130123257-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2013-05-16 | — | — | US | claimed |
| US-8415352-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-09 | — | — | US | claimed |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | claimed |
| EP-2247580-B1 | QUINOXALINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| US-8835634-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-8835634-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-20130123257-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130123257-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-8415352-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-09 | — | — | US | disclosed |
| US-8415352-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-09 | — | — | US | disclosed |
| US-8415352-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-09 | — | — | US | disclosed |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2247580-A1 | QUINOXALINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009109258-A1 | QUINOXALINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109258-A1 | QUINOXALINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123257-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | GPR119, IAPP, GLP1R | CFTR 626/4885KDM4E 3341/4885ALDH1A1 2371/4885 |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | GPR119, IAPP, GLP1R | CFTR 626/4885KDM4E 3341/4885ALDH1A1 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.